ArticleFrontiers in cardiovascular medicine2025
Incidence of atrial fibrillation and its association with long-term outcome in patients with an accessory pathway.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to examine the incidence of atrial fibrillation in patients with an accessory pathway (AP) and its association with transient ischemic attack (TIA)/stroke as well as mortality over long-term follow-up. Methods: A total of 1,302 consecutive patients who underwent first-time ablation AP between 2005 and 2018 were included from the Karolinska Ablation Registry and followed up through the National Patient Registry and Cause of Death Registry. Results: Patients were 41.7 ± 15.7 years old and 60.9% were men. New-onset or recurrence of atrial fibrillation occurred in 111 patients (8.5%) after a follow-up of up to 10 years (median 6.8 years; interquartile range 3.9-9.9 years). Multivariable analysis revealed that a history of atrial fibrillation, hyperlipidemia, a higher BMI, and older age were independently associated with new-onset or recurrence of atrial fibrillation during follow-up. All-cause mortality and TIA/stroke occurred in 35 patients (2.7%) and 28 patients (2.2%) after a follow-up of 10 years, respectively. Multivariable analysis revealed that the occurrence of atrial fibrillation during follow-up was independently associated with both outcomes. Conclusion: In this large patient cohort with ablated APs, long-term follow-up revealed a high incidence of atrial fibrillation with 8.5%. Occurrence of atrial fibrillation during follow-up was independently associated with both all-cause mortality and TIA/stroke. Hence, closer monitoring for atrial fibrillation is advisable in patients with ablated APs, especially in those with a prior history of atrial fibrillation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.